公开(公告)号：US11312713B2

公开(公告)日：2022-04-26

申请号：US16492558

申请日：2018-03-06

Applicant: Pfizer Inc.

Inventor： Michael Aaron Brodney ,  Thomas Allen Chappie ,  Jinshan Michael Chen ,  Jotham Wadsworth Coe ,  Karen Jean Coffman ,  Paul Galatsis ,  Michelle Renee Garnsey ,  Christopher John Helal ,  Jaclyn Louise Henderson ,  Bethany Lyn Kormos ,  Ravi G. Kurumbail ,  Luis Angel Martinez-Alsina ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Colin Richard Rose ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest ,  Travis T. Wager ,  Joseph Scott Warmus ,  Yuan Zhang

IPC: C07D471/04

Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

公开(公告)号：US09340493B2

公开(公告)日：2016-05-17

申请号：US14223061

申请日：2014-03-24

Applicant: Pfizer Inc.

Inventor： Matthew Frank Brown ,  Charles Francis Donovan ,  Edmund Lee Ellsworth ,  Denton Wade Hoyer ,  Timothy Allan Johnson ,  Manjinder Singh Lall ,  Chris Limberakis ,  Sean Timothy Murphy ,  Debra Ann Sherry ,  Clarke Bentley Taylor ,  Joseph Scott Warmus

IPC: A61K31/685 ,  A61K31/19 ,  A61K31/415 ,  A61K31/44 ,  A61K31/34 ,  A61K31/42 ,  A61K31/425 ,  A61K31/535 ,  C07D233/64 ,  C07D213/55 ,  C07D307/54 ,  C07C259/06 ,  C07D207/267 ,  C07D213/30 ,  C07D213/38 ,  C07D231/12 ,  C07D237/04 ,  C07D239/26 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D261/08 ,  C07D261/10 ,  C07D263/32 ,  C07D271/06 ,  C07D277/24 ,  C07D277/28 ,  C07D285/06 ,  C07D307/14 ,  C07D307/42 ,  C07D309/10 ,  C07D413/04 ,  C07D413/12 ,  C07D471/04 ,  C07F9/653 ,  C07D277/30

CPC classification number: C07C259/06 ,  C07C2601/04 ,  C07D207/267 ,  C07D213/30 ,  C07D213/38 ,  C07D213/55 ,  C07D231/12 ,  C07D233/64 ,  C07D237/04 ,  C07D239/26 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D261/08 ,  C07D261/10 ,  C07D263/32 ,  C07D271/06 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D285/06 ,  C07D307/14 ,  C07D307/42 ,  C07D307/54 ,  C07D309/10 ,  C07D413/04 ,  C07D413/12 ,  C07D471/04 ,  C07F9/653

Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II): and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B, L1-L4, A, B, R1-R4, and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中：G为式（II）的基团：及其药学上可接受的盐，前体药物，水合物或溶剂合物，其中A， B，L1-L4，A，B，R1-R4和m如本文所定义。 本发明还涉及包含式（I）化合物及其在治疗细菌感染中的用途的药物组合物。

公开(公告)号：US20140206651A1

公开(公告)日：2014-07-24

申请号：US14223061

申请日：2014-03-24

Applicant: Pfizer Inc.

Inventor： Matthew Frank Brown ,  Charles Francis Donovan ,  Edmund Lee Ellsworth ,  Denton Wade Hoyer ,  Timothy Allan Johnson ,  Manjinder Singh Lall ,  Chris Limberakis ,  Sean Timothy Murphy ,  Debra Ann Sherry ,  Clarke Bentley Taylor ,  Joseph Scott Warmus

IPC: C07C259/06 ,  C07D213/55 ,  C07F9/653 ,  C07D261/08 ,  C07D239/26 ,  C07D277/30 ,  C07D233/64 ,  C07D307/54

CPC classification number: C07C259/06 ,  C07C2601/04 ,  C07D207/267 ,  C07D213/30 ,  C07D213/38 ,  C07D213/55 ,  C07D231/12 ,  C07D233/64 ,  C07D237/04 ,  C07D239/26 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D261/08 ,  C07D261/10 ,  C07D263/32 ,  C07D271/06 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D285/06 ,  C07D307/14 ,  C07D307/42 ,  C07D307/54 ,  C07D309/10 ,  C07D413/04 ,  C07D413/12 ,  C07D471/04 ,  C07F9/653

Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II): and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B, L1-L4, A, B, R1-R4, and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中：G为式（II）的基团：及其药学上可接受的盐，前体药物，水合物或溶剂合物，其中A， B，L1-L4，A，B，R1-R4和m如本文所定义。 本发明还涉及包含式（I）化合物及其在治疗细菌感染中的用途的药物组合物。

公开(公告)号：US20170197939A1

公开(公告)日：2017-07-13

申请号：US15300440

申请日：2015-04-01

Applicant: PFIZER INC.

Inventor： Sharanjeet Kaur Bagal ,  Jingrong Jean Cui ,  Samantha Elizabeth Greasley ,  Elizabeth Ann Lunney ,  Indrawan James McAlpine ,  Asako Nagata ,  Sacha Ninkovic ,  Kiyoyuki Omoto ,  Sarah Elizabeth Skerratt ,  Robert Ian Storer ,  Joseph Scott Warmus

IPC: C07D401/14 ,  A61K31/4439 ,  C07D401/12

CPC classification number: C07D401/14 ,  A61K31/4439 ,  C07D401/12

Abstract: The present invention relates to compounds of Formula I and their prodrugs and pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.

公开(公告)号：US09328096B2

公开(公告)日：2016-05-03

申请号：US14705272

申请日：2015-05-06

Applicant: PFIZER INC

Inventor： Sharanjeet Kaur Bagal ,  Jingrong Jean Cui ,  Samantha Elizabeth Greasley ,  Elizabeth Ann Lunney ,  Indrawan James McAlpine ,  Asako Nagata ,  Sacha Ninkovic ,  Kiyoyuki Omoto ,  Sarah Elizabeth Skerratt ,  Robert Ian Storer ,  Joseph Scott Warmus

IPC: A61P35/00 ,  C07D413/14 ,  A61P29/00 ,  C07D405/14 ,  A61K31/4439 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D401/14 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.

Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐，其中取代基如本文所述，及其在药物中的用途，特别是作为TrkA拮抗剂。